Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function
M D Rapport1, G A Carlson, K L Kelly
1Department of Psychology, University of Hawaii, Honolulu 96822.
Insights
Methylphenidate and desipramine impact different cognitive functions in children with ADHD and mood disorders. Their combined effects show specific benefits for higher-order learning, suggesting targeted treatment approaches.
Area of Science:
- Child and Adolescent Psychiatry
- Neuropsychopharmacology
- Cognitive Neuroscience
Background:
- Attention-deficit hyperactivity disorder (ADHD) and mood disorders often co-occur in children.
- Understanding the cognitive effects of stimulant and antidepressant medications is crucial for treatment.
- Methylphenidate and desipramine are commonly used medications for these conditions.
Purpose of the Study:
- To investigate the separate and combined effects of methylphenidate and desipramine on cognitive functions.
- To examine these effects in psychiatrically hospitalized children with ADHD and mood disorder features.
Main Methods:
- A double-blind, placebo-controlled, crossover study design was employed.
- Cognitive functions assessed included vigilance, short-term memory, visual problem-solving, and higher-order learning.
Main Results:
- Methylphenidate monotherapy significantly improved vigilance.
- Both methylphenidate and desipramine positively impacted short-term memory and visual problem-solving.
- The combination of methylphenidate and desipramine enhanced the learning of higher-order relationships.
Conclusions:
- The cognitive effects of methylphenidate and desipramine are domain-specific.
- Combined drug administration yields distinct benefits for complex cognitive tasks.
- Findings have implications for understanding neurotransmitter systems involved in cognitive processes and mood regulation.
Objective:
The separate and combined effects of methylphenidate and desipramine on cognitive function were investigated in 16 psychiatrically hospitalized children with primary, secondary, and mixed features of attention-deficit hyperactivity disorder and mood disorder.
Method:
A double-blind, placebo controlled, crossover design was used to investigate drug effects on vigilance, short-term memory, visual problem solving, and higher-order learning.
Results:
Methylphenidate alone improved vigilance, both drugs positively affected short-term memory and visual problem solving, and combined drugs affected learning of higher-order relationships.
Conclusions:
Separate and combined drug effects are related to the specific cognitive domain assessed and have implications for neurotransmitter models of action.
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
10:02Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
Published on: March 12, 2020
Related Concept Videos
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
